formoterol fumarate

(redirected from Perforomist)
Also found in: Dictionary.
Related to Perforomist: Symbicort

formoterol fumarate

Atimos Modulite (UK), Foradil (UK), Foradil Aerolizer, Oxeze (CA), Oxis (UK), Perforomist

Pharmacologic class: Sympathomimetic; long-acting, selective beta2-adrenergic receptor agonist

Therapeutic class: Bronchodilator

Pregnancy risk category C


Stimulates intracellular adenylate cyclase, relaxing bronchial smooth muscle and inhibiting release of mediators of immediate hypersensitivity


Capsules for oral inhalation (used with Aerolizer inhaler): 12 mcg

Indications and dosages

Long-term maintenance of asthma; prevention or long-term maintenance of bronchospasm in patients with chronic obstructive pulmonary disease

Adults and children ages 5 and older: Contents of 1 capsule inhaled orally via Aerolizer q 12 hours

Acute prevention of exercise-induced bronchospasm (on occasional, as-needed basis)

Adults and children ages 5 and older: Contents of 1 capsule inhaled orally via Aerolizer at least 15 minutes before start of exercise. Wait 12 hours after initial dose before giving repeat dose.


• Hypersensitivity to drug or its components

• Tachyarrhythmias


Use cautiously in:

• acute asthma symptoms, deteriorating asthma, cardiovascular disorders, seizure disorders, thyrotoxicosis, diabetes, possible hypokalemia

• patients older than age 75

• labor

• pregnant or breastfeeding patients

• children younger than age 5.


• Be aware that drug is not intended for acute asthma attacks.

• Use capsules only with Aerolizer inhaler supplied.

• Keep capsules in blister until immediately before use.

Make sure patient doesn't swallow capsules.

Adverse reactions

CNS: tremor, dizziness, insomnia, anxiety

CV: chest pain

EENT: sinusitis, pharyngitis, tonsillitis

GI: dry mouth

Metabolic: hypokalemia, hyperglycemia

Musculoskeletal: muscle cramps, back pain, leg cramps

Respiratory: bronchitis, chest infection, dyspnea, upper respiratory tract infection, increased sputum

Skin: pruritus, rash

Other: dysphonia, viral infection, fever


Drug-drug. Adrenergics: potentiation of formoterol's sympathomimetic effects

Beta-adrenergic blockers: partial or total inhibition of formoterol's effects

Cardiac glycosides, methylxanthines, potassium-wasting diuretics, steroids: potentiation of formoterol's hypokalemic effects, increased risk of arrhythmias

Disopyramide, MAO inhibitors, quinidine, phenothiazines, procainamide, tricyclic antidepressants: prolonged QTc interval, increased risk of ventricular arrhythmias

Halogenated hydrocarbon anesthetics: increased risk of arrhythmias

Levodopa, levothyroxine, oxytocin: impaired cardiac tolerance of formoterol

Drug-diagnostic tests. Blood glucose: increased level

Potassium: decreased level

Drug-behaviors. Alcohol use: impaired cardiac tolerance of formoterol

Patient monitoring

• Monitor pulmonary function test results.

• Monitor potassium and glucose levels.

Patient teaching

• Teach patient how to use capsules and Aerolizer inhaler provided.

• Instruct patient to keep capsules in blisters until immediately before use.

• Caution patient not to swallow capsules.

• Tell patient not to use drug for acute asthma attacks.

Instruct patient to contact prescriber immediately if difficulty in breathing persists after using drug or if condition worsens.

• Caution patient to take drug exactly as prescribed and not to stop therapy even if he feels better.

• Tell patient to consult prescriber if he has been taking inhaled, short-acting drugs on a regular basis.

• Advise female patient to tell prescriber if she is pregnant or breastfeeding or if she plans to become pregnant.

• Caution patient to avoid alcohol during therapy.

• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

formoterol fumarate

(fôr-mō′tə-rôl′, -rōl′)
A drug used in the treatment of asthma, the prevention of bronchospasm, and the maintenance treatment of chronic obstructive pulmonary disease.

formoterol fumarate

a beta-adrenergic agonist used to treat chronic obstructive pulmonary disorder, maintain and treat asthma, and prevent exercise-induced bronchospasm.
Mentioned in ?
References in periodicals archive ?
a subsidiary of US Mylan Inc (NASDAQ: MYL), said on Tuesday that the US Patent and Trademark Office (USPTO) intends to reissue both of the patents related to Perforomist (formoterol fumarate) Inhalation Solution 20 mcg/2mL vial that had been placed into reexamination by Sepracor, now known as Sunovion Pharmaceuticals, part of Japan's Dainippon Sumitomo Pharma Co Ltd (TYO: 4506).
The terms of the patents protecting Perforomist extend into 2021.
Mylan is very pleased with Tuesday's decision by the USPTO in relation to intellectual property protecting Perforomist, as well as the company's combination product for the treatment of Chronic Obstructive Pulmonary Disease (COPD), currently in development, said Mylan chairman and CEO Robert Coury.
This patent covers Dey's Perforomist Solution, and its term extends until June 22, 2021.
Critical Therapeutics and DEY are promoting ZYFLO CR, ZYFLO and Perforomist to a targeted group of approximately 18,000 allergists, pulmonologists and primary care physicians throughout the United States.
including, without limitation, statements regarding our commercial launch of ZYFLO CR, possible therapeutic benefits, market acceptance and future sales of ZYFLO CR and ZYFLO, the anticipated success of our co-promotion arrangements with DEY, the anticipated commercial launch of Perforomist, the progress and timing of our drug development programs and related trials, the efficacy of our drug candidates, our strategy, future operations, financial position, future revenues and projected costs, including our net cash expenditures for 2007, prospects, plans and objectives of management, and all other statements that are not purely historical in nature, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.
Twice-daily Perforomist is approved for the long-term maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis.
Food and Drug Administration (FDA) approved DEY's new drug application for Perforomist for the long-term, twice-daily maintenance treatment of bronchoconstriction for emphysema and chronic bronchitis, also known as Chronic Obstructive Pulmonary Disease (COPD).
Under the terms of the definitive agreement, Critical Therapeutics and DEY, an affiliate of Merck KGaA of Darmstadt, Germany, will jointly promote Perforomist in the United States.